Patents by Inventor Paul Sanberg

Paul Sanberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9593070
    Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: March 14, 2017
    Assignee: UNIVERSITY OF SOUTH FLORIDA
    Inventors: Douglas Shytle, Paul Sanberg, Mary Newman, Archie A. Silver
  • Patent number: 9402870
    Abstract: Administration of human umbilical cord blood cells (HUCBC) or HUCBC-derived plasma is used to treat amyloid-based diseases, such as Alzheimer's disease, Huntington's disease, cerebral amyloid antigopathy, and type-II diabetes. Modulating inflammatory reactions by infusing HUCBC resulted in a marked reduction of amyloid plaques and immune-associated cellular damage. HUCBC infusion also significantly reduced cerebral amyloid angiopathy in mice models. These effects were associated with suppression of the CD40-CD40L interaction and a reduction in surface expressed CD-40 was observed on immune cells. Further, A? phagocytic activity was increased and soluble and insoluble A? protein levels were modulated by treatment. HUCBC-infused sera also significantly increased phagocytosis of A?1-42 peptide and inhibited immune cell CD40 expression and reduced cerebral amyloid angiopathy.
    Type: Grant
    Filed: February 16, 2010
    Date of Patent: August 2, 2016
    Assignee: University of South Florida
    Inventors: Jun Tan, Paul Sanberg
  • Publication number: 20140194525
    Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.
    Type: Application
    Filed: March 12, 2014
    Publication date: July 10, 2014
    Applicant: Targacept, Inc.
    Inventors: Douglas Shytle, Paul Sanberg, Mary Newman, Archie A. Silver
  • Patent number: 8574640
    Abstract: A method and composition for stimulating the proliferation and differentiation of stem cells is used to self-repair injury in mammals. A supplement is administered having an effective dose of blueberry, carnosine, catechin, green tea extract, VitaBlue, Vitamin D3 or combinations of these. For example, a therapeutic amount of two or more of the supplements may be selected having a synergistic effect, allowing a lower dose to achieve the same or greater effective protection as a higher dose of any one of the supplements.
    Type: Grant
    Filed: October 8, 2010
    Date of Patent: November 5, 2013
    Assignees: University of South Florida, The Department of Veterans Affairs, Natura Therapeutics, Inc.
    Inventors: Cyndy Davis Sanberg, Paula Bickford, Paul Sanberg, Jun Tan, R. Douglas Shytle
  • Patent number: 8309352
    Abstract: The present invention relates to the use of umbilical cord blood cells from a donor or patient to provide neural cells which may be used in transplantation. The isolated cells according to the present invention may be used to effect autologous and allogeneic transplantation and repair of neural tissue, in particular, tissue of the brain and spinal cord and to treat neurodegenerative diseases of the brain and spinal cord.
    Type: Grant
    Filed: November 9, 2006
    Date of Patent: November 13, 2012
    Assignee: University of South Florida
    Inventors: Paul Sanberg, Juan Sanchez-Ramos, Alison Willing, Daniel D. Richard
  • Patent number: 8026283
    Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.
    Type: Grant
    Filed: January 4, 2010
    Date of Patent: September 27, 2011
    Assignee: University of South Florida
    Inventors: Douglas Shytle, Paul Sanberg, Mary Newman, Archie A. Silver
  • Publication number: 20110038963
    Abstract: A method and composition for stimulating the proliferation and differentiation of stem cells is used to self-repair injury in mammals. A supplement is administered having an effective dose of blueberry, carnosine, catechin, green tea extract, VitaBlue, Vitamin D3 or combinations of these. For example, a therapeutic amount of two or more of the supplements may be selected having a synergistic effect, allowing a lower dose to achieve the same or greater effective protection as a higher dose of any one of the supplements.
    Type: Application
    Filed: October 8, 2010
    Publication date: February 17, 2011
    Inventors: Cyndy Davis Sanberg, Paul Sanberg, Paula Bickford, R. Douglas Shytle, Jun Tan
  • Publication number: 20110028565
    Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.
    Type: Application
    Filed: September 21, 2010
    Publication date: February 3, 2011
    Applicant: University of South Florida
    Inventors: Douglas Shytle, Paul Sanberg, Mary Newman, Archie A. Silver
  • Publication number: 20100286282
    Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.
    Type: Application
    Filed: January 4, 2010
    Publication date: November 11, 2010
    Applicant: Targacept, Inc.
    Inventors: Douglas Shytle, Paul Sanberg, Mary Newman, Archie A. Silver
  • Publication number: 20100150882
    Abstract: Administration of human umbilical cord blood cells (HUCBC) or HUCBC-derived plasma is used to treat amyloid-based diseases, such as Alzheimer's disease, Huntington's disease, cerebral amyloid antigopathy, and type-II diabetes. Modulating inflammatory reactions by infusing HUCBC resulted in a marked reduction of amyloid plaques and immune-associated cellular damage. HUCBC infusion also significantly reduced cerebral amyloid angiopathy in mice models. These effects were associated with suppression of the CD40-CD40L interaction and a reduction in surface expressed CD-40 was observed on immune cells. Further, A? phagocytic activity was increased and soluble and insoluble A? protein levels were modulated by treatment. HUCBC-infused sera also significantly increased phagocytosis of A?1-42 peptide and inhibited immune cell CD40 expression and reduced cerebral amyloid angiopathy.
    Type: Application
    Filed: February 16, 2010
    Publication date: June 17, 2010
    Applicant: UNIVERSITY OF SOUTH FLORIDA
    Inventors: Jun Tan, Paul Sanberg
  • Publication number: 20090280198
    Abstract: A method and composition for stimulating the proliferation and differentiation of stem cells is used to self-repair injury in mammals. A supplement is administered having an effective dose of blueberry, carnosine, catechin, green tea extract, VitaBlue, Vitamin D3 or combinations of these. For example, a therapeutic amount of two or more of the supplements may be selected having a synergistic effect, allowing a lower dose to achieve the same or greater effective protection as a higher dose of any one of the supplements.
    Type: Application
    Filed: October 23, 2008
    Publication date: November 12, 2009
    Inventors: Cyndy Davis Sanberg, Paul Sanberg, Paula Bickford, R. Douglas Shytle, Jun Tan
  • Patent number: 7442394
    Abstract: A method and composition for stimulating the proliferation and differentiation of stem cells is used to self-repair injury in mammals. A supplement is administered having an effective dose of blueberry, carnosine, catechin, green tea extract, VITABLUE® blueberry extract, Vitamin D3 or combinations of these. For example, a therapeutic amount of two or more of the supplements may be selected having a synergistic effect, allowing a lower dose to achieve the same or greater effective protection as a higher dose of any one of the supplements.
    Type: Grant
    Filed: May 2, 2006
    Date of Patent: October 28, 2008
    Assignee: University of South Florida
    Inventors: Cyndy Davis Sanberg, Paul Sanberg, Paula Bickford, R. Douglas Shytle, Jun Tan
  • Publication number: 20080206206
    Abstract: Bone marrow stromal cells (BMSC) differentiate into neuron-like phenotypes in vitro and in vivo, engrafted into normal or denervated rat striatum. The BMSC administered into the ventricle did not remain localized to the site of the graft, but migrated throughout the brain and integrated into specific brain regions in various architectonic patterns. The most orderly integration of BMSC was in the laminar distribution of cerebellar Purkinje cells, where the BMSC-derived cells took on the Purkinje phenotype. The BMSC exhibited site-dependent differentiation and expressed several neuronal markers including neuron-specific nuclear protein, tyrosine hydroxylase and calbindin. Treated BMSC implanted intrastriatally stayed in the cortex and the striatum, produced tyrosine hydroxylase which produces the dopamine needed in Parkinson's disease.
    Type: Application
    Filed: December 12, 2007
    Publication date: August 28, 2008
    Applicant: UNIVERSITY OF SOUTH FLORIDA
    Inventors: Juan Sanchez-Ramos, Shijie Song, William Janssen, Paul Sanberg, Thomas Freeman
  • Publication number: 20080089905
    Abstract: A method and composition for stimulating the proliferation and differentiation of stem cells is used to self-repair injury in mammals. A supplement is administered having an effective dose of substances selected from blueberry, carnosine, catechin, green tea extract, VitaBlue, Vitamin D3, Spirulina, AFA or effective combinations and derivatives of these. For example, a supplement comprising wild blueberry, green tea extract, carnosine, vitamin D3, and AFA-Omega (EtOH) or Spirulina and AFA-Omega (EtOH) exhibits a synergistic and unexpected association with substantially increased proliferation of bone marrow stem cells and CD34+. A therapeutic amount of a substance that is associated with a substantial increase in stem cells may be used to prevent and repair damaged tissues of the brain, due to stroke, the heart, due to coronary artery disease or a heart attack.
    Type: Application
    Filed: June 1, 2007
    Publication date: April 17, 2008
    Inventors: Cyndy Davis Sanberg, Paula Bickford, Paul Sanberg, Jun Tan, R. Shytle, Jerry Anderson
  • Publication number: 20080085330
    Abstract: A method and composition for stimulating the proliferation and differentiation of stem cells is used to self-repair injury in mammals. A supplement is administered having an effective dose of substances selected from blueberry, carnosine, catechin, green tea extract, VitaBlue, Vitamin D3, Spirulina, AFA or effective combinations and derivatives of these. For example, a supplement comprising wild blueberry, green tea extract, carnosine, vitamin D3, and a Spirulina and/or an AFA-Omega (EtOH) exhibited a synergistic and unexpected association with substantially increased proliferation of bone marrow stem cells and CD34+. A therapeutic amount of a substance that is associated with a substantial increase in stem cells may be used to prevent and repair damages tissues of the brain, due to stroke, the heart, due to coronary artery disease or a heart attack.
    Type: Application
    Filed: June 1, 2007
    Publication date: April 10, 2008
    Inventors: Cyndy Davis Sanberg, Paula Bickford, Paul Sanberg, Jun Tan, R. Shytle
  • Publication number: 20070237751
    Abstract: The present invention relates to the use of umbilical cord blood cells from a donor or patient to provide neural cells which may be used in transplantation. The isolated cells according to the present invention may be used to effect autologous and allogeneic transplantation and repair of neural tissue, in particular, tissue of the brain and spinal cord and to treat neurodegenerative diseases of the brain and spinal cord.
    Type: Application
    Filed: November 9, 2006
    Publication date: October 11, 2007
    Applicants: UNIVERSITY OF SOUTH FLORIDA, Saneron CCEL Therapeutics, Inc.
    Inventors: Paul Sanberg, Juan Sanchez-Ramos, Alison Willing, Daniel Richard
  • Patent number: 7160724
    Abstract: The present invention relates to the use of umbilical cord blood cells from a donor or patient to provide neural cells which may be used in transplantation. The isolated cells according to the present invention may be used to effect autologous and allogeneic transplantation and repair of neural tissue, in particular, tissue of the brain and spinal cord and to treat neurodegenerative diseases of the brain and spinal cord.
    Type: Grant
    Filed: March 7, 2001
    Date of Patent: January 9, 2007
    Assignee: University of South Florida
    Inventors: Paul Sanberg, Juan Sanchez-Ramos, Alison Willing, Daniel D. Richard
  • Publication number: 20060276551
    Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.
    Type: Application
    Filed: April 5, 2006
    Publication date: December 7, 2006
    Inventors: Douglas Shytle, Paul Sanberg, Mary Newman, Archie Silver
  • Publication number: 20060275512
    Abstract: A method and composition for stimulating the proliferation and differentiation of stem cells is used to self-repair injury in mammals. A supplement is administered having an effective dose of blueberry, carnosine, catechin, green tea extract, VitaBlue, Vitamin D3 or combinations of these. For example, a therapeutic amount of two or more of the supplements may be selected having a synergistic effect, allowing a lower dose to achieve the same or greater effective protection as a higher dose of any one of the supplements.
    Type: Application
    Filed: May 2, 2006
    Publication date: December 7, 2006
    Inventors: Cyndy Davis Sanberg, Paul Sanberg, Paula Bickford, R. Shytle, Jun Tan
  • Patent number: 7101916
    Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.
    Type: Grant
    Filed: May 19, 2003
    Date of Patent: September 5, 2006
    Assignee: University of South Florida
    Inventors: Douglas Shytle, Paul Sanberg, Mary Newman, Archie A. Silver